Mutant Prevention Concentration (MPC) of Ciprofloxacin against Salmonella enterica of epidemic and poultry origin

Current Microbiology

Volumn 62, Issue 2, 2011, Pages 628-632

  Ferrari, Rafaela ^a   Magnani, Marciane ^a   Souza, Roberta Barreiros ^a   Tognim, Maria Cristina Bronharo ^b   Oliveira, Tereza Cristina Rocha Moreira ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; NALIDIXIC ACID; SERINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; EPIDEMIC; GENE MUTATION; GROWTH INHIBITION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; POULTRY; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA ENTERITIDIS;

AMINO ACID SUBSTITUTION; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POULTRY; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; SALMONELLA INFECTIONS, ANIMAL;

SALMONELLA; SALMONELLA ENTERICA; SALMONELLA ENTERITIDIS;

EID: 79151479482     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-010-9754-7     Document Type: Article

References (25)

1. FM Aarestrup H Hasman L Olsen G Sorensen 2004 International spread of bla (CMY-2) mediated cephalosporin resistance in a multiresistant Salmonella enterica serovar Heidelberg isolate stemming from the importation of a boar by Denmark from Canada Antimicrob Agents Chemother 48 5 1916 1917 1:CAS:528:DC%2BD2cXjslCkt7c%3D 10.1128/AAC.48.5.1916-1917.2004 15105160 (Pubitemid 38544414)
2. WHO Global Salm-Surv (2006) Progress report (2000-2005): building capacity for laboratory-based foodborne disease surveillance and outbreak detection and response
3. Kottwitz LBM, Oliveira TCRM, Alcocer I et al (2010) Avaliaçã o epidemiológica de surtos de salmonelose ocorridos no período de 1999 a 2008 no Estado do Paraná, Brasil. Acta Scientiarum 32(1):9-15
4. I Escribano JC Rodríguez L Cebrian G Royo 2004 The importance of active efflux systems in the quinolone resistance of clinical isolates of Salmonella spp Int J Antimicrob Agents 24 5 428 432 1:CAS:528: DC%2BD2cXptFOnu7s%3D 15519472
5. DL Paterson 2006 Resistance in gram-negative bacteria: Enterobacteriaceae Am J Med 119 6 20 28 10.1016/j.amjmed.2006.03.013 (Pubitemid 43776142)
6. JA Crump TJ Barret JT Nelson FJ Angulo 2003 Reevaluating fluoroquinolone breakpoints for Salmonella enterica Serotype Typhi and for Non-Typhi Salmonellae Clin Infect Dis 37 1 75 81 10.1086/375602 12830411 (Pubitemid 36836648)
7. Q Zhang O Sahin PF Mcdermott S Payot 2006 Fitness of antimicrobial- resistant Campylobacter and Salmonella Microbes Infect 8 1972 1978 1:CAS:528:DC%2BD28Xns1Kjtb8%3D 10.1016/j.micinf.2005.12.031 16714138 (Pubitemid 44144559)
8. DC Hooper 2001 Emerging mechanisms of fluoroquinolone resistance Emerg Infect Dis 7 337 341 1:CAS:528:DC%2BD3MXjtFOqu7g%3D 10.3201/eid0702.010239 11294736
9. PM Hawkey 2003 Mechanisms of quinolone action and microbial response J Antimicrob Chemother 51 29 35 1:CAS:528:DC%2BD3sXktlOqu7w%3D 10.1093/jac/dkg207 12702701 (Pubitemid 36622102)
10. JM Blondeau 2004 Fluoroquinolones: mechanism of action, classification, and development of resistance Surv Ophthalmol 49 2 73 78 10.1016/j.survophthal. 2004.01.005 (Pubitemid 38353038)
11. X Zhao K Drlica 2001 Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies Clin Infect Dis 33 147 156 10.1086/321841 (Pubitemid 32835784)
12. CK Hesje GS Tillotson JM Blondeau 2007 MICs, MPCs and PK/PDs: a match (sometimes) made in hosts Expert Rev Respir Med 1 7 16 1:CAS:528: DC%2BD2sXhtV2rsbbI 10.1586/17476348.1.1.7 20477259
13. K Drlica 2003 The mutant selection window and antimicrobial resistance J Antimicrob Chemother 52 11 17 1:CAS:528:DC%2BD3sXltVSqtbY%3D 10.1093/jac/dkg269 12805267
14. Souza RB, Ferrari RG, Magnani M et al (2010) Ciprofloxacin susceptibility reduction of Salmonella strains isolated from outbreaks. Braz J Microbiol 41:497-500
15. Clinical and Laboratory Standards Institute (CLSI) (2006) Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement, Document M100-S16, Wayne PA
16. LP Randall SW Cooles LJ Piddock MJ Woodward 2004 Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica J Antimicrob Chemother 54 688 691 1:CAS:528:DC%2BD2cXnsVyhsLc%3D 10.1093/jac/dkh360 15243029 (Pubitemid 39263913)
17. F Pasquali G Manfreda 2007 Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa Vet Microbiol 119 304 310 1:CAS:528: DC%2BD2sXis1elug%3D%3D 10.1016/j.vetmic.2006.08.018 16987619 (Pubitemid 46027447)
18. C Kehrenberg A de Jong S Friederichs, et al. 2007 Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations J Antimicrob Chemother 59 5 886 892 1:CAS:528: DC%2BD2sXmt1emu7s%3D 10.1093/jac/dkm072 17369276 (Pubitemid 47073359)
19. E Giraud S Baucheron A Cloeckaert 2006 Resistance to fluoroquinolones in Salmonella: emerging mechanisms and resistance prevention strategies Microbes Infect 8 1937 1944 1:CAS:528:DC%2BD28Xns1KjtLg%3D 10.1016/j.micinf.2005.12.025 16714137 (Pubitemid 44144556)
20. S Feuerriegel P Heisig 2008 Role of global regulator Rma for multidrug efflux-mediated fluoroquinolone resistance in Salmonella Microbiol Drug Res 14 4 259 263 1:CAS:528:DC%2BD1cXhsFWis7vK 10.1089/mdr.2008.0846
21. F Gay A Robicsek J Strahilevitz, et al. 2006 Plasmid-mediated quinolone resistance in non-typhi serotypes of Salmonella enterica Clin Infect Dis 43 297 304 1:CAS:528:DC%2BD28XnvVKqtb0%3D 10.1086/505397 16804843 (Pubitemid 44078900)
22. E Giraud A Brisabois JL Martel E Chaslus-Dancla 1999 Comparative studies of mutation in animal isolates and experimental in vitro and in vivo selected mutants of Salmonella spp. suggest a counter selection of highly fluoroquinolones-resistant strains in the field AntimicrobAgents Chemother 43 2131 2137 1:CAS:528:DyaK1MXlvVGrtL8%3D
23. A Shah J Lettieri R Blum, et al. 1996 Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects J Antimicrob Chemother 38 103 116 1:CAS:528:DyaK28XltFWnur0%3D 10.1093/jac/38.1.103 8858462
24. EM Jones CM McMullin AJ Hedges, et al. 1997 The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intraabdominal disease J Antimicrob Chemother 40 121 124 1:CAS:528:DyaK2sXltVCit74%3D 10.1093/jac/40.1.121 9249215 (Pubitemid 27341644)
25. JE Varela SM Cohn M Brown, et al. 2000 Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries J AntimicrobChemother 45 337 342 1:CAS:528:DC%2BD3cXitV2jt7s%3D 10.1093/jac/45.3.337